Evidence map›Paper›PMID 40202541›Full record

ArticleActa neuropathologica2025

Diffuse astrocytoma, AYA-type, frequently MAPK-altered: report of 45 patients.

Omkar Singh, Christopher Dampier, Zied Abdullaev, Karen Dazelle, Hye-Jung Chung, Kyle Conway, Sandra Camelo-Piragua, Stewart Neill, Daniel Brown, James Stephen Nix and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Omkar SinghLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Christopher DampierLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Zied AbdullaevLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Karen DazelleLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hye-Jung ChungLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kyle ConwayDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Sandra Camelo-PiraguaDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Stewart NeillDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Daniel BrownCellNetix Laboratories, Seattle, WA, USA.
James Stephen NixDepartment of Medical Education, Alice L. Walton School of Medicine, Bentonville, AR, USA.
Caterina GianniniDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Robert MacaulayDepartment of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA.
Daniel MarkerDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
John SkaugenDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Scott KulichDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Han LeeDepartment of Pathology and Laboratory Medicine, Comprehensive Cancer Center, University of California- Davis, Sacramento, CA, USA.
Orwa AboudDepartment of Pathology and Laboratory Medicine, Comprehensive Cancer Center, University of California- Davis, Sacramento, CA, USA.
Peter PytelDepartment of Pathology, University of Chicago, Chicago, IL, USA.
Ewa BorysDepartment of Pathology and Laboratory Medicine, Loyola University, Maywood, IL, USA.
Arie PerryDepartments of Pathology and Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Laila Naqib-OsmanLower Columbia Pathologists, Longview, WA, USA.
Igor Lima FernandesLaboratorio Bacchi, Botucatu, Brazil.
Qinwen MaoDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Mouied AlashariDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Cheddhi ThomasDepartment of Pathology, Inova Fairfax Hospital, Fairfax, VA, USA.
Jeffrey HelgagerDepartment of Pathology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Maria A GubbiottiDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John NewmanDepartment of Pathology, Stanford University, Stanford, CA, USA.
Nishant TiwariDepartment of Pathology, Phoenix Children's Hospital, Phoenix, AZ, USA.
Patrick J CiminoSurgical Neurology Branch, Disorders and Stroke, National Institute of Neurological, National Institutes of Health, Bethesda, MD, USA.
Martha QuezadoLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kenneth D Aldape *Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
MacLean P Nasrallah *Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA. maclean.nasrallah@pennmedicine.upenn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A putative molecular subtype of IDH-wildtype diffuse glioma with recurrent MAPK pathway alterations has recently been reported. By dimensionality reduction analysis of genome-wide methylation profiling, these tumors form a distinct methylation cluster of gliomas. Characterization of 47 tumors from 45 patients reveals that these gliomas are predominantly supratentorial in young adults, are highly infiltrative, and harbor mitogen-activated protein kinase (MAPK) pathway alterations with high rates of CDKN2A/2B deletion, PDGFRA amplification, MYCN amplification, NF1 variants, and BRAF alterations. The tumors' epigenetics are distinct from other adult and pediatric gliomas in the 2021 World Health Organization (WHO) classification. The histology of the gliomas most often demonstrates high-grade astrocytic features, but can be variable from tumor to tumor, as well as fall into a spectrum of histologic grades. Outcomes show considerable variability based on histologic grade and molecular features, supporting grading within this group of tumors to ensure optimal care choices on an individual patient basis. These unifying epigenetic, sequencing, and infiltrative astrocytic features allow the tumors to be considered diffuse astrocytoma, adolescent, and young adult-type, with MAPK alterations (DAYA).

Indexed as

AstrocytomaBrain NeoplasmsMAP Kinase Signaling SystemMitogen-Activated Protein KinasesAdolescentAdultAgedChildDNA MethylationFemaleHumansMaleMiddle AgedYoung AdultMitogen-Activated Protein KinasesAYABrain tumorsEpigeneticsGliomaHGG_BMAPKMethylation profiling

Identifiers

PMID40202541
PMCPMC11982118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.